Grant Awarded for Device to Detect Newborn Heart Problems

LA BioMed Partnering with QT Medical to Identify Infants at Risk of Long QT Syndrome

LOS ANGELES – (Oct. 28, 2014) –Each year, some 2,000 babies are born in the U.S. with a genetic heart condition, known as long QT syndrome. If not diagnosed in time, babies with long QT syndrome can die from a sudden arrhythmia, or irregular heartbeat.

Advancing Innovation Gala to Honor Leaders of Companies Built on LA BioMed Research

Dr. John Michael Criley receiving an award

Event also Will Recognize Dr. John Michael Criley for His Leadership

LOS ANGELES – (September 24, 2014) – On Oct. 18 at its Advancing Innovation Gala, Los Angeles Biomedical Research Institute (LA BioMed) will recognize three champions of innovation who are leading companies built on research conducted at LA BioMed: Timothy Cooke, PhD., Keith Leonard and Yutaka Niihara, MD.

The Advancing Innovation Gala also will honor John Michael Criley, MD, an LA BioMed Legend and researcher, who pioneered the modern U.S. paramedic model of providing emergency care.

Universal Screening for MRSA May be Too Costly

Researchers Identify Why Hospitals May Not “Get in the Ring” to Fight “Superbug”

PHILADELPHIA – (Oct. 8, 2014) – Numerous experts and policy makers have called for hospitals to screen patients for methicillin-resistant Staphylococcus aureus (MRSA) infections and isolate anyone testing positive to prevent the spread of these so-called “Superbugs” in healthcare settings. Several states have enacted laws requiring patients be screened for MRSA upon admission.

Marijuana Use Associated with Lower Death Rates In Patients with Traumatic Brain Injuries

LA BioMed Researchers Surveyed Emergency Patients Tested for THC Levels

LOS ANGELES – (Oct. 1, 2014) – Surveying patients with traumatic brain injury, a group of Los Angeles Biomedical Research Institute (LA BioMed) researchers reported today that they found those who tested positive for THC, the active ingredient in marijuana, were more likely to survive than those who tested negative for the illicit substance.

Study Holds Hope of a Treatment For Deadly Genetic Disease, MPS IIIB

Researchers Find Method for Replacing Missing Enzyme in the Brain.

LOS ANGELES – (Oct. 1, 2014) – MPS IIIB is a devastating and currently untreatable disease that causes progressive damage to the brain, leading to profound intellectual disability, dementia and death — often before reaching adulthood.